MyoKardia is a clinical-stage biopharmaceutical company. Co.'s initial research has focused on genetic mutations in sarcomeric proteins of the heart muscle. Co.'s primary therapeutic candidate, mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). In addition to mavacamten, Co.'s programs include Danicamtiv, an orally-administered small molecule designed to increase cardiac contractility without impairing diastolic filling in patients with systolic heart failure; and MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation. The MYOK average annual return since 2015 is shown above.
The Average Annual Return on the MYOK average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MYOK average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MYOK average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|